Recursion Pharmaceuticals, Inc. RXRX Impairment of long-lived assets
Impairment of long-lived assets at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:TangibleAssetImpairmentCharges.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s impairment of long-lived assets.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s impairment of long-lived assets?
- Recursion Pharmaceuticals, Inc. (RXRX) reported impairment of long-lived assets of $0 in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s impairment of long-lived assets changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s impairment of long-lived assets decreased by 100.0% year-over-year, from $5.96M to $0.
- What does impairment of long-lived assets mean?
- Represents non-cash charges recognized when the carrying value of long-lived tangible assets exceeds their fair value. This metric indicates a reduction in the expected future economic benefit of physical assets, often signaling technological obsolescence or strategic shifts in operational focus.